Edwards Lifesciences · ISIN: US28176E1082

Edwards Lifesciences Reports Second Quarter Results

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8% Q2 TMTT sales reached $134.5 million or $133.0 million adjus...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 24.07.2025 | 22:15
24 July 2025 10:15PM
Edwards Lifesciences Reports Second Quarter Results
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8% Q2 TMTT sales reached $134.5 million or $133.0 million adjus...
Edwards Lifesciences
© BusinessWire
18 July 2025 01:05PM
Edwards Lifesciences to Host Earnings Conference Call on July 24, 2025
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2025 after the market closes on Thursday July 24, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be avail...
Edwards Lifesciences
© BusinessWire
22 May 2025 08:30AM
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on t...
Edwards Lifesciences
© BusinessWire
06 May 2025 01:05PM
Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference
Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on...
Edwards Lifesciences
© BusinessWire
01 May 2025 02:00PM
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients. Approval of the SAPIEN 3 platfo...
Edwards Lifesciences
© BusinessWire
23 April 2025 10:15PM
Edwards Lifesciences Reports First Quarter Results
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growt...
Edwards Lifesciences
© BusinessWire
18 April 2025 02:00PM
Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue
Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves. For more than 65 years, Edwards has been the leader in...
Edwards Lifesciences
© BusinessWire
16 April 2025 01:05PM
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be ava...
Edwards Lifesciences
© BusinessWire
14 April 2025 02:00PM
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System
Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the...
Edwards Lifesciences
© BusinessWire
31 March 2025 08:00PM
New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients
Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology’s (ACC) Annual Scientific Session & Expo, addressing the critical needs of patients with structural heart disease. Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis (AS) ma...
Edwards Lifesciences
© BusinessWire
25 February 2025 01:05PM
Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at...
Edwards Lifesciences
© BusinessWire
22 February 2025 04:50AM
EDWARDS LIFESCIENCES INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Edwards Lifesciences Corporation - EW
NEW ORLEANS, Feb. 21, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Edwards Lifesciences Corporation ("the Company") (NYSE: EW)....
Edwards Lifesciences
© PR Newswire
11 February 2025 10:15PM
Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups Q4 TAVR sales grew 6%; constant currency2 sales grew 5% Q4 TMTT sales grew 88% to $105 million with i...
Edwards Lifesciences
© BusinessWire
08 February 2025 01:20AM
EDWARDS LIFESCIENCES INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Edwards Lifesciences Corporation - EW
NEW ORLEANS, Feb. 7, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Edwards Lifesciences Corporation ("the Company") (NYSE: EW)....
Edwards Lifesciences
© PR Newswire
07 February 2025 11:43PM
EDWARDS LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Edwards Lifesciences Corporation - EW
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Edwards Lifesciences Corporation (“the Company”) (NYSE: EW). On July 24, 2024, the Company announced its financial results for the second quarter of the Fiscal Y...
Edwards Lifesciences
© BusinessWire
04 February 2025 01:05PM
Edwards Lifesciences to Host Earnings Conference Call on February 11, 2025
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also b...
Edwards Lifesciences
© BusinessWire
25 January 2025 12:33AM
EDWARDS LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Edwards Lifesciences Corporation - EW
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Edwards Lifesciences Corporation (“the Company”) (NYSE: EW). On July 24, 2024, the Company announced its financial results for the second quarter of the Fiscal Y...
Edwards Lifesciences
© BusinessWire
07 January 2025 01:05PM
Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation...
Edwards Lifesciences
© BusinessWire
13 December 2024 11:45AM
Levi & Korsinsky Reminds Edwards Lifesciences Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 13, 2024 - EW
NEW YORK, Dec. 13, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit se...
Edwards Lifesciences
© PR Newswire
12 December 2024 08:34PM
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edwards Lifesciences Corporation
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Edwards Lifesciences Corporation (“Edwards” or the “Company”) (NYSE: EW) and reminds investors of the December 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company....
Edwards Lifesciences
© BusinessWire
12 December 2024 07:42PM
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Edwards Lifesciences Corporation (EW)
The Law Offices of Frank R. Cruz reminds investors of the upcoming December 13, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Clas...
Edwards Lifesciences
© BusinessWire
12 December 2024 06:07PM
Faruqi & Faruqi Reminds Edwards Lifesciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 13, 2024 - EW
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi...
Edwards Lifesciences
© PR Newswire
12 December 2024 11:45AM
Edwards Lifesciences Corporation Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before December 13, 2024 to Discuss Your Rights - EW
NEW YORK, Dec. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encou...
Edwards Lifesciences
© PR Newswire
12 December 2024 02:31AM
EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit
BENSALEM, Pa., Dec. 11, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW). Class Period: February 6, 2024 – July 24, 2024Lead Plaintiff...
Edwards Lifesciences
© PR Newswire
11 December 2024 07:55PM
EW Deadline: Rosen Law Firm Urges Edwards Lifesciences Corporation (NYSE: EW) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024. Edwards describes itself as an “international company that researches, develops, provides products and tech...
Edwards Lifesciences
© BusinessWire
10 December 2024 11:49PM
EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit
NEW YORK, Dec. 10, 2024 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates...
Edwards Lifesciences
© PR Newswire
10 December 2024 06:00PM
EW Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Edwards Lifesciences Corporation (EW) Investors of Filing Deadline in Class Action Lawsuit
RADNOR, Pa., Dec. 10, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6,...
Edwards Lifesciences
© PR Newswire
10 December 2024 11:45AM
Levi & Korsinsky Notifies Shareholders of Edwards Lifesciences Corporation(EW) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, Dec. 10, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit se...
Edwards Lifesciences
© PR Newswire
09 December 2024 04:10PM
EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Dec. 9, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE: EW) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgate...
Edwards Lifesciences
© PR Newswire
09 December 2024 03:28PM
INVESTOR DEADLINE FRIDAY: Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - EW
SAN DIEGO, Dec. 9, 2024 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), have until this Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lif...
Edwards Lifesciences
© PR Newswire
09 December 2024 11:45AM
Edwards Lifesciences Corporation Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - EW
NEW YORK, Dec. 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encour...
Edwards Lifesciences
© PR Newswire
06 December 2024 06:16AM
EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit
  NEW YORK, Dec. 6, 2024 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both date...
Edwards Lifesciences
© PR Newswire
05 December 2024 10:02PM
EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit
LOS ANGELES, Dec. 5, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW)....
Edwards Lifesciences
© PR Newswire
05 December 2024 05:18PM
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edwards Lifesciences Corporation
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi...
Edwards Lifesciences
© PR Newswire
05 December 2024 11:45AM
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Edwards Lifesciences Corporation(EW) Shareholders
NEW YORK, Dec. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encour...
Edwards Lifesciences
© PR Newswire
05 December 2024 01:00AM
EW Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Edwards Lifesciences Corporation
RADNOR, Pa., Dec. 4, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 20...
Edwards Lifesciences
© PR Newswire
04 December 2024 04:00PM
EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Dec. 4, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE: EW) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgate...
Edwards Lifesciences
© PR Newswire
04 December 2024 12:00PM
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial guidance today during its annual investor conference. Edwards enters 2025, its first full year as a purely structural heart company, in a s...
Edwards Lifesciences
© BusinessWire
03 December 2024 11:45AM
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Edwards Lifesciences Corporation(EW) Shareholders
NEW YORK, Dec. 3, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit see...
Edwards Lifesciences
© PR Newswire
03 December 2024 01:01AM
Lead Plaintiff Deadline on December 13, 2024 for EW Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class...
Edwards Lifesciences
© BusinessWire
02 December 2024 09:52PM
EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit
LOS ANGELES, Dec. 2, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW)....
Edwards Lifesciences
© PR Newswire
02 December 2024 11:57AM
EW INVESTOR ALERT: Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
SAN DIEGO, Dec. 2, 2024 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, all dates inclusive (the "Class Period"), have until Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edward...
Edwards Lifesciences
© PR Newswire
02 December 2024 11:45AM
Edwards Lifesciences Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - EW
NEW YORK, Dec. 2, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit see...
Edwards Lifesciences
© PR Newswire
01 December 2024 03:54AM
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edwards Lifesciences Corporation
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi...
Edwards Lifesciences
© PR Newswire
30 November 2024 05:00PM
EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit
NEW YORK, Nov. 30, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates...
Edwards Lifesciences
© PR Newswire
29 November 2024 04:00PM
EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Nov. 29, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE: EW) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgat...
Edwards Lifesciences
© PR Newswire
28 November 2024 06:00PM
Lead Plaintiff Deadline Approaching in EW: Kessler Topaz Meltzer & Check, LLP Reminds Investors A Securities Fraud Class Action Has Been Filed Against Edwards Lifesciences Corporation
RADNOR, Pa., Nov. 28, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2...
Edwards Lifesciences
© PR Newswire
28 November 2024 01:57AM
EW Case Alert: Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the Edwards Lifesciences Corporation Class Action
SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Robbins LLP reminds investors that a class action (Case No. 24-cv-02221) was filed on behalf of all investors who purchased or otherwise acquired Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024. Edwards is an international company that researches, develops,...
Edwards Lifesciences
© PR Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.